scroll
for
more

Once-daily dose

at the same time each day

No dosing differences with Lantus® (insulin glargine injection) 100 units/mL for insulin initiation1,2

Type 2 diabetes: recommended starting dose 0.2 units/kg once daily or up to 10 units once daily Type 2 diabetes: recommended starting dose 0.2 units/kg once daily or up to 10 units once daily
  • Adjustments to the amount and timing of short- or rapid-acting insulins and dosages of any anti-diabetic medications may be necessary
Type 1 diabetes: recommended starting dose of ~1/3 of the total daily insulin requirements Type 1 diabetes: recommended starting dose of ~1/3 of the total daily insulin requirements
  • Short- or rapid-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements
  • BASAGLAR must be used concomitantly with short-acting insulin

Other dosing information1

  • Inject BASAGLAR subcutaneously once a day, any time of day, at the same time every day
  • Individualize and titrate BASAGLAR dosage based on the metabolic needs, blood glucose monitoring results, and glycemic control goal of the individual
  • Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), during acute illness, or changes in renal or hepatic function, and should be made under medical supervision with appropriate glucose monitoring

titrate BASAGLAR®

(insulin glargine injection) 100 units/mL

TO target FPG levels4,10

less than or equal to 100 mg/dL or FPG based on goal of individual patient less than or equal to 100 mg/dL or FPG based on goal of individual patient

FPG=fasting plasma glucose.

  • Dose titration of BASAGLAR should be individualized according to patient needs and performed under the guidance of a healthcare professional
  • In the event of hypoglycemia, a dose reduction may be necessary

FPG=fasting plasma glucose.

transitioning

to BASAGLAR®

(insulin glargine injection) 100 units/mL

BASAGLAR dosing should be the same as Lantus when transitioning patients from Lantus1

From Lantus® (insulin glargine injection) 100 units/mL

The dose of BASAGLAR should be the same as Lantus and the time of day for administration should be determined by the healthcare professional.

Transitioning from other insulins1

From Toujeo® (insulin glargine injection) 300 units/mL

The recommended initial BASAGLAR dosage is 80% of the Toujeo dose that is being discontinued. This dosage reduction will lower the likelihood of hypoglycemia.

From intermediate- or long-acting insulin other than Lantus

A change in the dose of BASAGLAR may be required and the amount and timing of shorter-acting insulins and doses of any anti-diabetic drugs may need to be adjusted.

From twice-daily NPH insulin

The recommended initial BASAGLAR dosage is 80% of the total NPH dosage that is being discontinued. This dosage reduction will lower the likelihood of hypoglycemia.

NPH=Neutral Protamine Hagedorn.

Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.1

begin with the BASAGLAR®

(insulin glargine injection) 100 units/mL

prefilled KWIKPEN®

Prefilled BASAGLAR KwikPen—a similar design to other Lilly KwikPens

  • Delivers between 1 and 80 units of BASAGLAR in a single injection11
  • Up-down dial adjustment in 1-unit increments for selecting BASAGLAR dose11
  • Works with BD Ultra-Fine™ needles11*
  • No refrigeration needed after first injection—store at room temperature up to 86°F (30°C) after first use and dispose after 28 days1,11†
Not actual size

Delivers between 1 and 80 units of BASAGLAR in a single injection11

Up-down dial adjustment in 1-unit increments for selecting BASAGLAR dose11

BASAGLAR (insulin glargine injection) 100 units/mL prefilled KwikPen®

Works with BD Ultra-Fine™ needles11*

No refrigeration needed after first injection—store at room temperature up to 86°F (30°C) after first use and dispose after 28 days1,11

BASAGLAR KwikPen must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.1

In patients with type 1 diabetes, BASAGLAR must be used concomitantly with short-acting insulin.1

*Multiple sizes may be used.
Do not freeze or use a KwikPen that has been frozen.